www.ijarp.com ISSN 2456-9992 Page: 01-24

International Journal Advanced Research Publications

Research Article

Volume: 02
Issue: 04

"VIRTUAL BODIES, REAL RESPONSES: THE RISE OF DIGITAL TWINS IN PHARMACODYNAMICS"

Ms. S. Nandhini[1]*, Ms. S. Priyanka[2], Ms. G.S. Mowsika[3], Ms. S. Priyanka[4], Ms. M. Madhumithra[5], Ms. V. Sulochana[6], Dr. G. Rathinavel[7]

[1]Assistant professor, Department of Pharmaceutics, K.S. Rangasamy college of Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.

[2]Department of Pharmacy, B-Pharm, K.S. Rangasamy college of Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.

[3]Department of Pharmacy, B-Pharm, K.S. Rangasamy college of Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.

[4]Department of Pharmacy, B-Pharm, K.S. Rangasamy college of Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.

[5]Assistant professor, Department of Pharmaceutical chemistry, K.S. Rangasamy college of Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.

[6]Lecturer, Department of Pharmacology, K S Rangasamy college of Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.

[7]Professor & Principal, Department of Pharmaceutical chemistry, K.S. Rangasamy college of Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.

The Tamilnadu Dr.M.G.R Medical University, Chennai, Tamil Nadu, India.

Article Received: 28 February 2026, Article Revised: 18 March 2026, Published on: 08 April 2026

***Corresponding Author: Ms. S. Nandhini**

Assistant professor, Department of Pharmaceutics, K.S. Rangasamy college of Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.

DOI: https://doi-doi.org/101555/ijarp.5776

ABSTRACT:

By making it possible to create dynamic, patient-specific virtual models that mimic medication response and illness development, digital twin technology represents an emerging paradigm in pharmacodynamics. The primary goal of pharmacodynamics is to comprehend how drug concentration and biological reaction are related, but prediction accuracy is frequently hampered by inter- individual variability.

Digital twins create computational copies that can forecast treatment outcomes by integrating multi-source biomedical data, such as physiological, molecular, and clinical factors. This method lowers attrition rates, increases safety profiling, facilitates virtual clinical trials, and improves dose optimization in drug development. Digital twins support precision medicine and more effective regulatory evaluation by facilitating simulation-based study of toxicity and efficacy before to actual delivery. Notwithstanding difficulties with data protection, infrastructure needs, validation, and ethical issues, the technology provides revolutionary promise for clinical treatments and pharmaceutical research. Digital twins are anticipated to play a key role in contemporary pharmacodynamic analysis and individualized treatment plans as computer modelling, systems pharmacology, and real-time health data integration develop.

KEYWORDS: Pharmacodynamics, Computer modelling, Systems pharmacology, Toxicity.

INTRODUCTION:

Among the most crucial ideas in the dose-response relationship is known as pharmacodynamics [6]. This relationship explains how a drug's effect intensifies as its Concentration or dose increases(1). The response might be quantal, where it is all-or-none, or graded, where the effect grows gradually.(9)Pharmacodynamic evaluation relies heavily on A basic area of pharmacology called pharmacodynamics examines the physiological and biochemical effects of medications as well as their mechanisms of action. It mainly looks at by early scientists like Paul Ehrlich, who suggested that medications work by attaching to biological receptors(8). Subsequent advances in dose-response relationships and receptor occupancy theory offered a mathematical foundation for assessing pharmacological effect.

Fig. No. 01

A parameter like the therapeutic index, Emax (maximum effect), and EC50 (effective concentration causing 50% of maximal effect). Direct and indirect response models are two frequent classifications for pharmacodynamic models [6].Direct response models make the assumption that the observed effect and medication concentration are directly correlated. Drug activity that alters physiological mediators or biological processes over time is taken into account by indirect response models(8). Drug-effect relationships are frequently described using turnover models, log-linear models, and sigmoid Emax models. Pharmacodynamics revolves around drug-receptor interactions. Drug could as inverse agonists, antagonists, partial agonists, or agonists(3). While antagonists prevent receptor activation, agonists cause biological reactions by activating receptors. A drug's pharmacodynamic behaviour is influenced by its intrinsic activity and affinity. Pharmacodynamic responses are caused by a variety of factors, including age, gender, genetic polymorphisms, organ function, disease status, tolerance, and drug interactions [7]. For instance, genetic differences in signal transduction pathways or receptor expression can drastically change treatment results. In evaluating toxicity, pharmacodynamics is equally crucial. Exaggerated pharmacological effects or inadvertent receptor interaction are common causes of adverse medication responses. Determining appropriate therapeutic limits and reducing toxicity are made easier by analyzing concentration-effect relationships [7].



Fig. No. 02

When developing drugs, advanced computational and improve pharmacodynamics prediction accuracy have been possible by changing environment made pharmacodynamic research is

incorporated into both preclinical and clinical phases. Assays conducted in vitro assess the potency and affinity of receptors(11). Systemic pharmacodynamic data are obtained from animal research. Clinical trials evaluate safety, effectiveness, and dose selection in human populations(7). Pharmacodynamic reactions are frequently measured using biomarkers as surrogate endpoints. Despite Improvements, traditional pharmacodynamic methods still have drawbacks(3). Because of biological complexity, translating preclinical discoveries to humans is still difficult(8). Inter-individual variability may not be sufficiently considered by population- based dosage techniques(4). Clinical studies are costly, time-consuming, and can end in failure because of poor efficacy prediction.



Fig. No. 03

The need for customized pharmacodynamic evaluation is rising as precision medicine gain more attention(8). To customize medication regimens for every patient, personalized medicine necessitates the integration of molecular, physiological, and clinical data(6).



Fig. No. 04

The scientific field of pharmacodynamics (PD) studies how medications affect the body biologically(8). It focuses on how drug molecules interact with biological targets—such as receptors, enzymes, ion channels, or transporters— and looks at how these interactions result in quantifiable physiological and clinical reactions(2). The concentration –effect relationship, which establishes drug potency, efficacy, therapeutic index, and overall safety profile, is fundamental to pharmacodynamics [8]. Pharmacodynamics offers the basis for logical dose selection and treatment optimization by examining how different medication concentrations affect the strength and duration of response(7). In the late 19th and early 20th centuries, pharmacodynamic theory developed concurrently with receptor theory(4). In order to guide sensible medication therapy and guarantee patient safety, parameters like EC50 (the effective concentration producing 50% of the maximal effect), Emax (the maximum attainable response), and the therapeutic window (the range between effective and quantal responses are the two main categories of pharmacodynamic reactions. Graded reactions change continually with dosage, with it possible to gauge an individual's level of influence [9].



Fig. No. 05

For instance, if drug concentration rises, changes in blood pressure or enzyme activity may also rise proportionately. Quantal responses, on the other hand, reflect all-or-none outcomes that are seen throughout a community, like the existence or lack of mortality prevention or seizure control(9). Complementary information regarding drug action and safety is provided by these two response kinds. Characterizing pharmacodynamic interactions requires the use of mathematical modeling.(8)



Fig. No. 06

Direct response models make the assumption that the medication concentration the site of action directly affects the observed effect(8). Indirect response models take into consideration circumstances when the medication affects the synthesis or removal of endogenous mediators, leading to effects that are either amplified or delayed(6).

When medication effects show saturation at higher dosages, sigmoid Emax models are very helpful in describing nonlinear concentration- response curves(7). PK-PD models, which explain both the time course of drug concentration and the accompanying impact, are frequently created by integrating these pharmacodynamic models with pharmacodynamic (PK) data [9]. Understanding the initiation, intensity, and duration of action is improved by such integration.



Fig.No.07

Pharmacodynamics has a number of difficulties despite its quantitative basis and scientific accuracy. Due to their interwoven signalling pathways, feedback mechanisms, compensatory responses, and regulatory network, biological systems are intrinsically complex(6). Rarely does drug action happen in a vacuum; rather, it interacts with dynamic physiological processes that may alter or negate therapeutic effects. Furthermore, inter-individual variability has a major impact on pharmacodynamic results. Drug sensitivity may be impacted by genetic variants that change signal transduction pathways, enzyme activity, or receptor shape. Variability in response is further influenced by age-related changes, organ dysfunction (especially hepatic or renal impairment), illness condition, environmental exposures, lifestyle factors, and drug-drug interactions. Population-based dosage techniques may not always provide the best therapeutic results for every patient because of these factors(12). Clinical trials that show average responses within particular populations are

usually the source of standardized dosage regimens(13). Individual patients may, however, differ significantly from these averages, which could result in inadequate treatment, therapeutic failure, or unfavourable drug reactions.(4)



Fig.No.08

This diversity highlights the need for more individualized methods of treatment decision-making and pharmacodynamic assessment. The limits of traditional pharmacodynamics are further demonstrated by drug development(19). Due to inadequate efficacy or unanticipated toxicity, a significant percentage of medication candidates fail late-stage clinical studies. Because of species differences and simplified experimental circumstances, preclinical research carried out invitro or in animal models frequently fail to precisely anticipate human responses, although providing crucial mechanistic insights(17). The intricacy of human physiology and diseases heterogeneity may be beyond the scope of even the most sophisticated PK-PD models. Pharmaceutical research has high attrition rates, higher development costs, and longer timetables as a result of these constraints. Traditional pharmacodynamic frameworks are further challenged by the increasing complexity of contemporary medicines, such as targeted anticancer drug, gene therapies, and biologics. Predicting response is made much more difficult by the fact that these treatments frequently entail complex modes of action, immunological regulation, or customized molecular targets(16). As a result, novel approaches that can improve prediction accuracy and enable tailored treatment are desperately needed. A viable approach to overcoming these constraints is the use of digital twin technology, Digital twins are dynamic computational models that mimic that behaviour, track performance, and forecast results [10]. They were first created in

the engineering and aerospace sectors to produce virtual reproductions of physical systems. Digital twins have the ability to create customized virtual models of patients, organs, or disease systems when used in pharmacodynamics(13). These models can simulate drug responses, forecast treatment results, and optimize dosing regimens prior to actual administration by combining clinical, molecular, and physiological data. This strategy has the potential to improve precision medicine, lessen side effects, and increase drug development efficiency [10].

IMPORTANCE: Understanding pharmacodynamics (PD) is essential to comprehending how medications affect the body. It entails researching the connection between the therapeutic or harmful reaction that results from a drug's concentration at the site of action(18). Determining the ideal dosage, therapeutic index, medication efficacy, and safety all depend on accurate pharmacodynamic modelling. Clinical studies, animal models, and in vitro research are major components of traditional pharmacodynamic evaluation [11]. Nevertheless, these techniques are costly, time-consuming, and can inaccurately forecast human reactions because of biological variability. (7)



Fig.No.9

Response is greatly influenced by inter-individual heterogeneity brought on by genetic variations, age, sex, comorbidities, and environmental factors(22). High attrition rates are linked to drug development, particularly in phase II and III clinical trials mostly because of unexpected toxicity or ineffectiveness. Drug development failure rates can be considerably decreased by improving pharmacodynamic prediction(23). Furthermore, rather than using a

“one- size- fits-all” strategy, personalizes medicine necessitates customized dosing strategies. Targeted therapy, less adverse drug reactions, and better therapeutic outcomes are all made possible by precise pharmacodynamic understanding.

Therefore, enhancing pharmacodynamic modelling is crucial for: Increasing the effectiveness of drugs lowering toxicity. Reducing the cost of clinical trials. Quickening the approval of drugs. Facilitating accuracy [12].

How medications cause both beneficial and harmful effects in human body is largely determined by pharmacodynamics. Choose the right dosages, guaranteeing medication safety, and optimising clinical efficacy all depend on an understanding of the concentration-effect relationship(28). However, population averages and controlled experimental settings are frequently used in conventional pharmacodynamic evaluation, which may not adequately represent the represent the heterogeneity seen in actual patients. In this regard, digital twin technology has been a significant development that improves pharmacodynamics science’s potential for prediction and customization. The capacity of digital twins to address inter-individual heterogeneity in drug response is one of the main reasons they are significant in pharmacodynamics [13]. Genetic composition, metabolic capacity, immunological response, receptor sensitivity, age, organ function, and illness severity all vary greatly among patientsConventional dosage schedules, which are based on average clinical trial data, might not give every patient the best results. The enhancement of dose optimization is another crucial factor.

Fig.No.10

Digital twin models can replicate organ-level reactions, such as hepatic metabolism or cardiac electrophysiology, Pharmacovigilance and patient safety are improved by this

predictive capability [14]. Digital twins also aid in the development of precision medicine. Individualized therapy is becoming more and more important in modern healthcare as opposed to standardized treatment plans. The goal of precision medicine is to customize medication selection and dosage according to physiological, molecular, and genetic traits(25). A structured computational framework for combining these various data source into useful pharmacodynamic predictions is offered by digital twins.



Fig.No.11

PHARMACODYNAMICS:

CONVECTIONAL METHODS: Pharmacodynamics used the following traditional techniques prior to digital twin integration.

In vitro Research Drug potency is assessed using cell-based assays, receptor- binding studies, and enzyme inhibition models (EC50, IC50). They do not, however, have complicated whole-body physiology [16].

Models of Animals Systematic response data is obtained through animal research. Interspecies diversity, however, restricts human translation [17].

PK-PD Modeling Drug concentration-effect connections are mathematically described by pharmacokinetic- pharmacodynamic (PK-PD) models. Among them are: Models of direct effects. Models of indirect responses. Emax sigmoid models. Despite their strength, these models frequently include assumptions about population averages [18].



Fig.No.12

Clinical Experiments Safety and effectiveness are evaluated in human experiments. Nevertheless, they are costly and time-consuming. Patient variety is limited morally limited [19].Monitoring Based on Biomarkers Although biomarkers are used to evaluate treatment response, they could not adequately represent the complexity of the disease. Although fundamental, traditional approaches lack predictive adaptability and real-time customisation [20].

INNOVATIVE APPLICATION:

Digital twin technology simulates biological behaviour by combining digital models with real-world patient data.Simulation of Patient-Specific Optimization of Dose Optimizing dosage schedules according to each person's metabolic capacity is made possible via virtual simulation.Modelling the progression of Disease To forecast treatment results, digital twins can stimulate long-term conditions like cancer, diabetes, and cardiovascular diseases

[22].Online Clinical Research Clinical trials can be stimulated by large populations of digital twins, saving money and time [23].Biomarker Identification Predictive biomarkers are found by AI-driven twin model analysis [24]. Modelling Rare Diseases Digital twins offer virtual cohorts for research in situations when patient numbers are constrained [26].



Fig.No.13

ADVANTAGE:

Impact and benefits of AI in pharmacodynamics AI have become a game- changing tool in the pharmaceutical sciences, especially in pharmacodynamics. The area of pharmacology known as pharmacodynamics examines how medications interact with biological systems and whether these interactions result in positive or negative outcomes(32). Large-scale clinical trials, statistical analysis, animal studies, and laboratory experiments have all historically played a significant role in pharmacodynamic research(32). Even though these techniques have greatly aided in the development of new drugs, they are costly, time-consuming, and occasionally unable to adequately capture the complexity of biological systems. Researchers and clinicians can increase individualized treatment approaches, optimize therapeutic procedures, and improve drug development by utilizing AI tools(25). AI is therefore becoming more significant in contemporary pharmaceutical research and healthcare innovation [27].



Fig.No.14

Better prediction of drug response accurately predicting medication responses is one of AI's most significant benefits in pharmacodynamics. Individual variances in genetics, metabolism, age, lifestyle, and medical conditions all have a substantial impact on drug reaction conventional pharmacodynamic models frequently depend on population averages, which could not adequately reflect patient responses(34). Large datasets with genomic data, protien interaction metabolic pathways, and medical records can all be analysed by AI systems. AI can forecast how particular medication will interact with biological targets like receptors, enzymes,or signaling molecules by spotting intricate patterns in these datasets. Research can better understand how medication work and how difference in biological systems could affect treatment result by using these predictive models(43). Additionally, AI-based prediction model lessens the need for trail-and-error methods in medication treatment. AI- supported technologies allow doctors to predict possible patient reaction and choose the best course of action. This lowers the possibility of ineffective therapy and increase the effectiveness of treatment [28].



Fig.No.15

One of the most important in pharmacodynamics is figuring out the ideal dosage of a medication. While excessive dosing can result in toxicity and negative side effects,low dosing may not have the intended therapeutic effect. Conventional dosage method frequently depend on the set rule that might not take patients variation into consideration(40). Artificial intelligence offers strong instruments evaluating pharmacokinetics and pharmacodynamics in order to identify the best dosage plans. Numerous factor,including drug concentration receptor binding affinity , metabolic rate, and patient characteristic ,can be assessed by machine learning algorithms . AI systems can suggest customized dosage schedules that optimize treatment efficacy while reducing side effects by concurrently evaluating these variables .For medications with limited therapeutic windows, where accurate dosage is crucial for patient safety,this strategy is especially beneficial [30].



Fig.No.16

Early drug toxicity identification

One of the main causes of drug development failure and a frequent reason for bad medication reaction in clinical practice is drug toxicity(33). To, maintain patient safety and minimize financial losses in pharmaceutical research, it is crucial to identify hazardous effects early in the medication development process. AI algorithm are able predict possible harmful effects of medication candidates by analysing biological interaction network and chemical structures. By comparing novel chemical with medication that have already been investigated, machine learning algorithms can find patterns linked to toxicity. For instance, by examine how medication interact with cardiac ion channels,AI- based models can forecast cardiotoxicity(22). Similarly, by analying metabolic pathways related to liver function, AI can identify possible hepatoxicity . Researchers can remove dangerous substance before they reach the expensive stage of cinical trails by detecting toxicity early on [36].

Assistance with online clinical trials

Clinical trials are crucial for assessing the efficacy and safety of novel medication . But they need a lot of time,money, and participants. The creation of virtual clinical trails is aided by artificial intelligence can replicate drug testing in virtual patient population using computational models. AI is capable of creating virtual patients with a variety of physiology ,genetic,and demographic traits. Then ,in order to assess medication effectiveness and any adverse effects, researches can model various treatment scenarios. Before actual trails start,these simulation offer in sightful information about clinical outcomes. Virtual clinical trails assist reasearches in creating more effective studies ,cutting expenses, and lowering hazards to human subjects. AI – based simulation offer a valuble supplementary tool in contemporary drug discovery even though actual clinical trails are still crucial [31].

DISAVANTAGE: Drawbacks and ethical corners of artificial intelligence in pharmacodynamics by enhancing drug discovery, treatment optimization ,and predictive modeling ,artificial intelligence (AI) has profoundly changed pharmaceutical research and pharmacodynamics. The application of AI in pharmacodynamics presents a number of drawbacks and ethical issue despite its numerous benefits. Risks to data privacy,algorithms bias, lack of transparency

,difficulties with regulations, and possible abuse of private health data are some of these problems. In order to guarantee the safe, equitable, and responsible application of the technology, is crucial to carefully address these ethical and technological issues as AI

continues to be incorporated into pharmaceutical science and healthcare [32)



Fig.No.17

Data security and privacy issue protecting patient data is one of the most important ethical corners related ti AI in pharmacodynamics. Large amounts of biological data,such as genetic information,medical records, and clinical trails outcomes,are needed for AI system and lifestyle information(35). This data is extermely sensitive and needs to be handled with caution to aviod abuse. Confidential health information may be exposed through data breaches, cyberattacks ,or unauthorized access if appropriate security measures are not put in place,such violation mat jeopardize patient privacy and result in the improper use of private health data .Genetic or medical information,for instance ,may be used to discriminate in insurance or employment(11) . Therefore,while utilizing AI system in pharmacodynamic research and clinical application,it is crucial to provide secure data storage,encryption and stringent access control [33].

Algorithm bias and inequality

Algorithm prejudice is another significant issue. AI system learns on past data,and if the training data is biased only includes members of particular demographics , the predictions made by AI models could be skewed. Example,an AI model may not reliably predict drug response in underrepresented population if it is trained mostly on data from specific ethnic groups or geographic areas. Healthcare inequities and differential treatment results may result(42). Biased algorithms in pharmacodynamic may suggest inappropriate medication dosage or treatment for specific patient population , thereby jeopardizing the efficacy and safety of treatment. To reduce bias ,research must make sure AI models are trained on representative and diverse datasets [34].

Lack of transparency and explainability

Especially deep learning system, operate as black boxes, making it challenging to understand how they make decision.

Although these models can generate quite precise forecasts, it is frequently unclear how they arrive at those conclusions. Transparency is crucial in pharmacology and healthcare(12). Before implementing therapy recommendations in patient care, clinical and research must comprehend the rationale behind them. Healthcare practioners may find it challenging to trust or validate the outcomes if AI system make prediction without providing clear reason. Clinical uptake and regulatory approval may also be hampered by this lack of explainability(9). Therefore, creating explainable AI models that offer intelligence insights into drug –body interaction is crucial field of study [36].

FUTURE SCOPE: Future potential of AI in pharmacodynamics. Future advancements in pharmacodynamics are anticipated to be significantly influenced by artificial intelligence [37]. AI will present new chances to enhance comprehension of drug –body interaction, optimize treatment approaches, and expedite pharmaceutical research as computational technology and biochemical data collection continue to progress. In the upcoming years, drug development and clinical practice are likely change due to the integration of AI with contemporary healthcare technologies [38]. The development of individualized medicine is one important of future path.(9)



Fig.No.18

Research and medical professionals will be able to examine patient-specific data, including genetic information, metabolic profiles, disease biomakers,and lifestyle factors, thanks to AI system [39]. The creation and use of digital twin technology is another exciting field. Virtual representation of individuals or biological system that mimic physiological function and medication reaction are called digital twin(23). Research and medical professionals may be able to test various treatment approaches in a simulated setting before implementing them in actual patients in the future thanks to digital twins. This strategy can lower the posibility of unanticipated adverse effects and AI –supported clinical trials and real –time patient monitoring may also be used more frequently in the future .To monitor patient reaction, AI system can examine health data from wearable technology and electronic health records to ongoing therapy(25) . This will enhance patient safety and enable medical practitioners to swiftly modify treatments. In conclusion AI has a very bright future in pharmacodynamics. AI will eventually shape the contemporary medicine by facilitating more effective medication research, better treatment plans and superior patient care with ongoing technological breakthroughs [41].



Fig.No.19

CONCLUSION

In the realm of pharmacodynamics, artificial intelligence (AI) has emerged as a crucial instrument that presents fresh chances to advance drug development and pharmaceutical research [42].AI makes it easier for researchers to evaluate big, complicated biological datasets by utilizing cutting – edge technology like machine learning and data analytics [43] . Better medication response prediction treatment strategy improvement and the creation of personlized medicine techniques that can enhance patient outcomes are all made possible by this capability [44]. Despite these advantage, these are a number of drawbacks and moral dilemmans with using AI in pharmacodynamics

. Care must be taken when addressing issues including algorithm prejustice, data privacy , hazards, opaque AI decision –making and regulatory obstacles. Maintainig confidence in AI-based healthcare system requires safeguarding private patient data and creating impartial and equitable algorithm [45]. Furthermore, rather than tsking the place of human knowledge and clinical judgement ,AI should be utilized as a helpful tool strong ethical standard. Appropriate legal frameworks,and ongoing AI system monitoring are required to guarantee responsible usuage AI. To manage these issues ,cooperation between scientists ,medical pratitioners,legislators, and tech specialists will be crucial . In conclusion , even though AI has some hazards and moral delemmas, when used sensibly and morally , it has the ability to revolutionize pharmacodynamics research and enhance medication therapy [46] .

REFERENCE

1. **Viceconti, M., & Henriques, T. (2021).** Digital twins in healthcare: A review of the current state and future perspectives. Journal of Healthcare Engineering, 2021, 1-12.
2. **Karimi, S., & Karimi, M. (2022).** Applications of digital twin technology in pharmacodynamics and personalized medicine. Journal of Personalized Medicine, 12(3), 435-450.
3. **Zhang, L., & Zhang, J. (2022).** Artificial intelligence in pharmacodynamics: Current status and future perspectives. Journal of Pharmaceutical and Biomedical Analysis, 217, 114823.
4. **Kenakin, T. (2018). Pharmacodynamics:** A century of progress. British Journal of Pharmacology, 175(11), 2109-2122.
5. **Wright, D. F. B., & Duffull, S. B. (2019).** Pharmacodynamic modeling: A historical perspective. CPT: Pharmacometrics & Systems Pharmacology, 8(5), 261-271.
6. **Mager, D. E., & Jusko, W. J. (2008).** Pharmacodynamic modeling of time-dependent pharmacological systems. Journal of Pharmacokinetics and Pharmacodynamics, 35(2), 145-166.
7. **Danhof, M., & Breimer, D. D. (2018).** The role of pharmacodynamics in the development of new drugs. European Journal of Pharmaceutical Sciences, 122, 1-8.
8. **Peck, C. C., & Cross, J. T. (2001).** Pharmacodynamics: A historical perspective. Journal of Clinical Pharmacology, 41(7), 727-736.
9. **Viceconti, M., & Henriques, T. (2021).** Digital twins in healthcare: A review of the current state and future perspectives. Journal of Healthcare Engineering, 2021, 1-12.
10. **Karimi, S., & Karimi, M. (2022).** Applications of digital twin technology in pharmacodynamics and personalized medicine. Journal of Personalized Medicine, 12(3), 435-450.
11. **Li, X., & Li, Y. (2023).** Digital twin-enabled pharmacodynamic modeling for precision medicine. Journal of Pharmacokinetics and Pharmacodynamics, 50(2), 141-155.
12. **Pauwels, E., & De Clercq, E. (2022).** Digital twins in drug development: Opportunities and challenges. Drug Discovery Today, 27(5), 1031-1038.
13. **Zhang, Y., & Wang, J. (2022).** Digital twins in pharmacology: A new paradigm for precision medicine. Pharmacological Reviews, 74(3), 555-573.
14. **Goodman & Gilman's** The Pharmacological Basis of Therapeutics (14th ed.). McGraw-Hill Education. (Chapter 2: Pharmacodynamics)
15. **Kenakin, T. (2009).** A Pharmacology Primer: Theory, Applications, and Methods (3rd

ed.). Academic Press.

16. **Derendorf, H., & Mehta, D. K. (2016).** Pharmacodynamics: Principles and Applications. In S. C. Gad (Ed.), Pharmaceutical Sciences (pp. 1-18). Springer.
17. **Wright, D. F. B., & Duffull, S. B. (2013)**. Pharmacodynamic models: What you need to know. British Journal of Clinical Pharmacology, 75(3), 561-571. doi: 10.1111/j.1365-2125.2012.04391.x
18. **Viceconti, M., & al. (2020).** Digital twins for personalized medicine: A scoping review. npj Digital Medicine, 3(1), 1-11. doi: 10.1038/s41746-020- 0301-x
19. **Laubenbacher, R., & al. (2020).** Digital twins for predictive medicine. Journal of Computational Biology, 27(4), 542-555. doi: 10.1089/cmb.2019.0288
20. **Schwaiger, T., & al. (2020)**. Digital twins in healthcare: A review of the current state and future perspectives. Journal of Healthcare Engineering, 2020, 1-12. doi: 10.1155/2020/8848881
21. **Corral-Acero, J., & al. (2020).** Digital twins in cardiovascular medicine: A review of the current state and future perspectives. Journal of Cardiovascular Translational Research, 13(3), 437-451. doi: 10.1007/s12265- 020- 10014-1
22. **Karolak, A., & al. (2021)**. Digital twins in pharmacology: A review of the current state and future perspectives. Journal of Pharmacokinetics and Pharmacodynamics, 48(2), 143-159. doi: 10.1007/s10928-021-09751-1
23. **Niederer, S. A., & al. (2020)**. Digital twins for personalized medicine: A review of the current state and future perspectives. Journal of Personalized Medicine, 10(4), 141. doi: 10.3390/jpm10040141
24. **Zhang ,L& al** Artificial intelligence in pharmacodynamics: A review of the current state and future perspectives. Journal of Pharmacokinetics and Pharmacodynamics, 47(2), 123-141. doi: 10.1007/s10928-020- 09691-1 - Lee, J., & al. (2020). Machine learning-based prediction of drug response in cancer patients. Journal of Clinical Oncology, 38(15_suppl), 12001-12001. doi: 10.1200/JCO.2020.38.15_suppl.12001
25. Acceleration of drug discovery and development:**Chen, H., & al. (2020).** Artificial intelligence in drug discovery and development. Nature Reviews Drug Discovery, 19(1), 1-18. doi: 10.1038/nrd.2019.214
26. **Sushmita, S., & al. (2020).** AI-driven drug discovery: A review of the current state and future perspectives. Journal of Chemical Information and Modeling, 60(2), 541-553. doi: 10.1021/acs.jcim.9b0079
27. ***Enhanced modeling of complex biological systems*: - Eung-Hee, J., & al. (2020)**.

Artificial intelligence-based modeling of complex biological systems. Journal of Computational Biology, 27(4), 556-569. doi: 10.1089/cmb.2019.0289 - Kuo, C. H., & al. (2020). Machine learning-based modeling of biological systems. Journal of Theoretical Biology, 485, 110071. doi: 10.1016/j.jtbi.2019.110071

28. Optimization of drug dosage and treatment strategies:**Wang, Y., & al. (2020)**. Artificial intelligence-based optimization of drug dosage and treatment strategies. Journal of Clinical Pharmacology, 60(2), 141-153. doi: 10.1002/jcph.1571
29. **Zhang, Y., & al. (2020).** Machine learning-based optimization of treatment strategies for cancer patients. Journal of Clinical Oncology, 38_suppl), 12002-12002. doi: 10.1200/JCO.2020.38.15_suppl.12002
30. ***Early identification of drug toxicity*: - Liu, X., & al. (2020).** Artificial intelligence-based prediction of drug toxicity. Journal of Chemical Information and Modeling, 60(2), 554-565. doi: 10.1021/acs.jcim.9b00792 - Zhang, L., & al. (2020). Machine learning-based prediction of drug-induced liver injury. Journal of Clinical Pharmacology, 60(2), 154-165. doi: 10.1002/jcph.1572
31. **Fan Y., Wu Y., Wang Z. (2025)** – Exploring the ethical issues posed by AI and big data technologies in drug development. Frontiers in Public Health, 13:1585180. Discusses privacy risks, bias, and lack of transparency in AI-driven pharmaceutical research.
32. **Dankwa-Mullan I. (2024)** – Health Equity and Ethical Considerations in Using Artificial Intelligence in Public Health and Medicine. CDC Public Health Commentary, 21. Highlights how missing or under-representative data leads to algorithmic bias and health inequities.
33. **Sabet C.J., Tamirisa K., Bitterman D.S., Celi L.A. (2025)** – Regulating medical AI before midnight strikes: Addressing bias, data fidelity, and implementation challenges. PLOS Digital Health, 4(8):e0000986. Covers regulatory gaps, accountability, and data-fidelity concerns.
34. **Panagopoulos A., Minssen T., Sideri K., Yu H., Compagnucci M.C. (2024)** – Balancing Privacy and Progress: A Review of Privacy Challenges, Systemic Oversight, and Patient Perceptions in AI-Driven Healthcare. Applied Sciences, 14(2):675. Examines data-privacy challenges and security measures needed for medical AI.
35. **Smith J., Lee R. (2023)** – Explainability and transparency in AI-driven pharmacodynamics. Journal of Biomedical Informatics, 138:104212. Explores the black-box problem and the need for interpretable models in drug-response prediction.
36. **Li B., Tan K., Lao A.R., Wang H., Zheng H., Zhang L. (2024)** – A comprehensive

review of artificial intelligence for pharmacology research. Frontiers in Genetics, 15:1450529. Covers AI-driven personalized medicine, drug-response prediction, and integration with genomics/proteomics.

37. **Saratkar S.Y., Langote M., Kumar P., Gote P., Weerarathna I.N., Mishra G.V. (2025)** – Digital twin for personalized medicine development. Frontiers in Digital Health, 7:1583466. Explains how digital-twin models simulate patient-specific drug responses and support real-time treatment testing.
38. **Johnson K.B., Wei W.Q., Weeraratne D., Frisse M.E., Misulis K., Rhee K. (2021)** – Precision medicine, AI, and the future of personalized health care. Clinical & Translational Science, 14(1):86-93. Discusses AI-enabled patient-specific dosing and outcome prediction.
39. **Tanoli Z., Vähä-Koskela M., Aittokallio T. (2021**) – Artificial intelligence, machine learning, and drug repurposing in cancer. Expert Opinion on Drug Discovery, 16(9):977-989. Shows how AI accelerates drug-candidate screening and toxicity prediction.
40. **Wang S., Di J., Wang D., et al. (2024)** – The artificial intelligence-powered new era in pharmaceutical formulation. AAPS Journal, 26(1):19. Reviews AI integration with big-data (genomics, metabolomics) for faster drug development and real-time monitoring
41. **Fan Y., Wu Y., Wang Z. (2025)** – Exploring the ethical issues posed by AI and big data technologies in drug development. Frontiers in Public Health, 13:1585180. Emphasizes privacy protection, bias mitigation, and responsible oversight.
42. **Dankwa-Mullan I. (2024)** – Health Equity and Ethical Considerations in Using Artificial Intelligence in Public Health and Medicine. CDC Commentary, 21. Stresses fairness, transparency, and human-in-the-loop judgment.
43. **Sabet C.J., Tamirisa K., Bitterman D.S., Celi L.A. (2025**) – Regulating medical AI before midnight strikes. PLOS Digital Health, 4(8):e0000986. Calls for regulatory frameworks and accountability mechanisms.
44. **Panagopoulos A., Minssen T., Sideri K., et al. (2024)** – Balancing Privacy and Progress. Applied Sciences, 14(2):675. Details privacy risks and governance recommendations.
45. **J., Lee R. (2023)** – Explainability and transparency in AI-driven pharmacodynamics. J. Biomedical Informatics, 138:104212. Advocates for interpretable models and clinician oversight.